Furthermore, CASC9 exerts its oncogenic activity by modulating TGFβ2 (transforming growth factor beta‐2) mRNA stability and upregulating the levels of TGFβ2 and TERT (telomerase reverse transcriptase), resulting in an increase in phosphorylated SMAD3 (SMAD family member 3), activation of TGF‐β signaling, and enhanced TERT complex function in colorectal cancer cells (K. Luo et al., 2019). This evidence concerns the gene CASC9 and colorectal cancer.